



# Intervening in the High-Risk Patient Before a CV Event: The Role of PCSK9 Inhibition



Recorded live on:

**May 5, 2026**

7:00 - 8:00 pm EDT



## Milan Gupta

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor, Department of Medicine,  
University of Toronto  
Medical Director,  
Collaborative CME and Research Network  
Brampton, ON

**View this recorded discussion on  
the VESALIUS-CV trial with Dr.  
Lawrence Leiter (Key Investigator).**

Explore the role of evolocumab in preventing first major cardiovascular events in high-risk patients without prior MI or stroke, and gain practical insights for your clinical practice.

### Learning Objectives

- Identification of high-risk patients without prior CV events
- Discuss the spectrum of primary vs. secondary CV prevention
- Learn about the role of evolocumab in patients with subclinical atherosclerosis or high-risk diabetes



Click here to view at [ccrnm.com](https://ccrnm.com)

SPEAKERS



## Lawrence A. Leiter

MD, FRCPC, FACP, FACE, FAHA, FACC

Division of Endocrinology and Metabolism,  
St. Michael's Hospital  
Professor of Medicine and Nutritional Sciences,  
University of Toronto  
Toronto, ON

Developed By



For program inquiries, contact:  
[info@ccrnm.com](mailto:info@ccrnm.com)

This program has received unrestricted educational funding from Amgen Canada.

